[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-433007-105":59,"doc-detail-433007-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","whats-new-in-heart-failure-november-2025-editorial","What’s new in heart failure? - November 2025 Editorial","","European Journal of Heart Failure 2025 editorial presents concise summaries of newly published studies relevant to heart failure specialists. Key topics include how heart failure patients with a history of malignancy differ in clinical profile and outcomes, echocardiographic phenotyping of cardiac wasting in advanced cancer, and the role of sacubitril/valsartan for cancer therapy-related cardiac dysfunction in early breast cancer. Additional coverage links centre volume with cardiogenic shock outcomes in Germany.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/whats-new-in-heart-failure-november-2025-editorial/433007/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/whats-new-in-heart-failure-november-2025-editorial/433007.png","ImageObject",300,407,{"name":92,"@type":93},"Indoniesian Boy","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-29",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What question does the editorial address about heart failure and cancer history?","Question",{"text":112,"@type":113},"It summarizes evidence on how often heart failure patients have prior malignancy and how this affects clinical profile, treatment patterns, and mortality or hospitalization outcomes.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What echocardiographic pattern is described for cardiac wasting-associated cardiomyopathy?",{"text":117,"@type":113},"Patients with advanced cancer and low left ventricular mass show a distinct phenotype with reduced chamber volumes, stroke volume, and cardiac output, while left ventricular ejection fraction and global longitudinal strain remain normal.",{"name":119,"@type":110,"acceptedAnswer":120},"Why does the editorial emphasize integrated cardio-oncology care?",{"text":121,"@type":113},"It highlights poorer non-cardiovascular outcomes in heart failure patients with prior cancer and suggests that HFrEF patients with malignancy may receive less guideline-directed medical therapy, supporting the need for coordinated care and appropriate clinical-trial inclusion.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},433007,1790766206,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":81,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":39,"preview_page_count":4},962090760608,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","European Journal of Heart Failure (2025) 27, 1947–1949 EDITORIAL  \n doi:10.1002/ejhf.70089  \nWhat’s new in heart failure? November 2025  \nMert Tokcan 1,2, Julian Hoevelmann 1,2,3, Philipp Markwirth 1,  \nand Bernhard Haring 1,2,4,5 *  \n1 Department of Internal Medicine III, Saarland University Hospital, Homburg/Saar, Germany; 2 HOMICAREM (HOMburg Institute of CArdioREnalMetabolic Medicine), Medical Faculty, Saarland University, Saarbrücken, Germany; 3 Cape Heart Institute, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa; 4 Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, USA; and 5 Department of Medicine IV, Clinic Hietzing, Vienna Healthcare Group, Vienna, Austria  \nIn this column, we want to provide clinicians and researchers with short and concise summaries of recently published studies in the European Journal of Heart Failure that we think may be of particular relevance to heart failure (HF) specialists (Figure 1). Key topics of this issue include characteristics and outcomes of patients with HF and history of malignancy, echocardiographic phenotyping of cardiac wasting in advanced cancer patients, the effect of sacubitril/valsartan for primary prevention of cancer therapy-related cardiac dysfunction (CTRCD) in early breast cancer and the associations between centre volume and cardiogenic shock (CS) outcomes in Germany.  \nHistory of malignancy in patients with heart failure: insights from the Swedish Heart Failure Registry  \nCancer and HF frequently coexist. 1,2 However, data on the clinical profile, treatment patterns, and outcomes of HF patients with a history of malignancy are scarce.3,4  \nAmeri et al.5 analysed 53 314 patients from the Swedish Heart Failure Registry linked to the National Cancer Register between 2000 and 2020 to address this gap. Among these, 9066 patients (17%) had a prior cancer diagnosis made more than 2 years before HF diagnosis. The most prevalent malignancies were prostate (26%), breast (15%), colorectal (11%), and haematologic cancers (11%). Patients with a history of cancer were typically older, more often female, and exhibited a higher comorbidity burden, including atrial fibrillation, anaemia, and chronic obstructive pulmonary disease. Over a median follow-up of 2.4 years, mortality rates per 100 patient-years were higher in those with previous cancer (24; 95% confidence interval [CI] 23–25) compared with those without (18; 95% CI 18–19). Prior cancer was independently associated with an increased risk of all-cause mortality (adjusted hazard ratio [HR] 1. 14; 95% CI 1.11–1. 18),  \n...................................................... ........................................................  \nnon-cardiovascular death (HR 1.38; 95% CI 1.31–1.44), and first all-cause hospitalization (HR 1. 11; 95% CI 1.09–1. 14), whereas no association was observed with cardiovascular death or first HF hospitalization. Importantly, the excess risk of non-cardiovascular death declined progressively with increasing time since the last cancer diagnosis. In patients with HF with reduced ejection fraction (HFrEF), a history of malignancy was associated with less frequent use of guideline-directed medical therapy, including device therapy (cardiac resynchronization therapy/implantable cardioverter-defibrillator).  \nIn summary, this large, population-based analysis highlights that a history of cancer is common in HF and associates with poorer non-cardiovascular outcomes. Furthermore, HFrEF patients with prior malignancy appear to be undertreated with regard to guideline-directed medical HF therapy. These findings emphasize the need for integrated cardio-oncology care and careful consideration of including this high-risk subgroup in future clinical trials.  \nEchocardiographic phenotype of cardiac wasting in advanced cancer patients  \nCardiac wasting-associated cardiomyopathy is characterized by a loss of left ventricular mass and is an emergin","cbCaipoIody3Woyo","https://ap.wps.com/l/cbCaipoIody3Woyo","pdf",567228,"English","# What’s new in heart failure? November 2025\n## Heart failure and history of malignancy\n## Echocardiographic phenotype of cardiac wasting in advanced cancer patients","[{\"question\":\"What question does the editorial address about heart failure and cancer history?\",\"answer\":\"It summarizes evidence on how often heart failure patients have prior malignancy and how this affects clinical profile, treatment patterns, and mortality or hospitalization outcomes.\"},{\"question\":\"What echocardiographic pattern is described for cardiac wasting-associated cardiomyopathy?\",\"answer\":\"Patients with advanced cancer and low left ventricular mass show a distinct phenotype with reduced chamber volumes, stroke volume, and cardiac output, while left ventricular ejection fraction and global longitudinal strain remain normal.\"},{\"question\":\"Why does the editorial emphasize integrated cardio-oncology care?\",\"answer\":\"It highlights poorer non-cardiovascular outcomes in heart failure patients with prior cancer and suggests that HFrEF patients with malignancy may receive less guideline-directed medical therapy, supporting the need for coordinated care and appropriate clinical-trial inclusion.\"}]","What’s new in heart failure? - November 2025 Editorial | PDF",1790662303]